Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accounts Payables (2019 - 2026)

Biodesix filings provide 8 years of Accounts Payables readings, the most recent being $3.7 million for Q1 2026.

  • On a quarterly basis, Accounts Payables rose 24.82% to $3.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.7 million, a 24.82% increase, with the full-year FY2025 number at $3.1 million, up 40.38% from a year prior.
  • Accounts Payables hit $3.7 million in Q1 2026 for Biodesix, up from $3.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.7 million in Q1 2026 to a low of $1.6 million in Q1 2023.
  • Median Accounts Payables over the past 5 years was $2.9 million (2023), compared with a mean of $2.6 million.
  • Biggest five-year swings in Accounts Payables: tumbled 43.42% in 2022 and later skyrocketed 105.57% in 2024.
  • Biodesix's Accounts Payables stood at $1.7 million in 2022, then surged by 73.83% to $2.9 million in 2023, then dropped by 25.09% to $2.2 million in 2024, then surged by 40.38% to $3.1 million in 2025, then increased by 18.54% to $3.7 million in 2026.
  • The last three reported values for Accounts Payables were $3.7 million (Q1 2026), $3.1 million (Q4 2025), and $3.6 million (Q3 2025) per Business Quant data.